Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 8/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926085 | 0.89 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2931161 | 0.89 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL2932540 | 0.87 | CYP1A1 (0.48) | ALDH1A1MAPTGAAKMT2AHTT | |
| SCHEMBL2924811 | 0.85 | PDE4D (0.49) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL2930876 | 0.85 | PDE4D (0.49) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL1157640 | 0.85 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL2930361 | 0.83 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2932678 | 0.83 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2925828 | 0.82 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2931743 | 0.82 | PDE4B (0.46) | PDE4APDE4BPDE4CPDE4DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653134-B2 | Hydroxyphenol derivatives, processes for the preparation thereof, pharmaceutical compositions them, and therapeutic uses thereof | MERCK PATENT GMBH (DE) | 2014-02-18 | — | — | US | claimed |
| EP-1569908-B1 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARM CORP (US) | 2010-09-15 | — | — | EP | claimed |
| EP-1836150-B1 | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2010-09-15 | — | — | EP | claimed |
| US-20100173942-A1 | PHOSPHODIESTERASE 4 INHIBITORS | SCHUMACHER RICHARD A | 2010-07-08 | — | — | US | claimed |
| US-7700631-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-20 | — | — | US | claimed |
| US-20080161308-A1 | e.g. 4-[6-(2-cyclohexylethoxy)-3-oxoindan-5-yloxy]butanoic acid; peroxisome proliferator-activated receptor (PPAR) gamma agonist; antiinflammatory, antidiabetic agent; dyslipidaemia, atherosclerosis, insulin resistance | MERCK PATENT GMBH (DE) | 2008-07-03 | — | — | US | claimed |
| EP-1836150-A1 | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC USES THEREOF | Merck Patent GmbH (DE) | 2007-09-26 | — | — | EP | claimed |
| US-20060211865-A1 | Use of pyridine N-oxide analogs at doses which do not induce emesis | SCHUMACHER RICHARD A | 2006-09-21 | — | — | US | claimed |
| US-7087625-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-08-08 | — | — | US | claimed |
| WO-2006074798-A1 | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2006-07-20 | — | — | WO | claimed |
| EP-1569908-A2 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| US-20040152902-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-08-05 | — | — | US | claimed |
| WO-2004046113-A2 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-06-03 | — | — | WO | claimed |
| US-8653134-B2 | Hydroxyphenol derivatives, processes for the preparation thereof, pharmaceutical compositions them, and therapeutic uses thereof | MERCK PATENT GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| EP-1569908-B1 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARM CORP (US) | 2010-09-15 | — | — | EP | disclosed |
| EP-1836150-B1 | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2010-09-15 | — | — | EP | disclosed |
| US-20060211865-A1 | Use of pyridine N-oxide analogs at doses which do not induce emesis | SCHUMACHER RICHARD A | 2006-09-21 | — | — | US | disclosed |
| US-7087625-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| WO-2006074798-A1 | HYDROXYPHENOL DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THERAPEUTIC USES THEREOF | MERCK PATENT GMBH (DE) | 2006-07-20 | — | — | WO | disclosed |
| US-20040152902-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161308-A1 | e.g. 4-[6-(2-cyclohexylethoxy)-3-oxoindan-5-yloxy]butanoic acid; peroxisome proliferator-activated receptor (PPAR) gamma agonist; antiinflammatory, antidiabetic agent; dyslipidaemia, atherosclerosis, insulin resistance | PPARG, PPARA, PPARD | PDE4A 1284/4885PDE4B 1902/4885PDE4C 2642/4885 |
| US-20100173942-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885 |
| US-20060211865-A1 | Use of pyridine N-oxide analogs at doses which do not induce emesis | PDE4A, PDE4B, PDE3B | PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885 |
| US-20040152902-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE3B | PDE4A 1/4885PDE4B 2/4885PDE4C 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.